The Pharma Data

JULY 8, 2021

ADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia. Food and Drug Administration (FDA) has approved an updated label for ADUHELM (aducanumab-avwa) injection 100 mg/mL solution. ADUHELM is indicated for the treatment of Alzheimer’s disease.

Clinical Trials 52

Clinical Trials FDA Approval Trials FDA 52

The Pharma Data

JANUARY 6, 2021

UNION therapeutics A/S is a privately held, clinical stage, pharmaceutical company dedicated to the development of novel treatments for inflammatory and infectious diseases. The Company is working on two complementary chemistry classes spanning immunology and microbiology and has five candidates in clinical development.

FDA Approval 52

FDA Approval FDA Clinical Development Clinical Research 52

The Pharma Data

DECEMBER 29, 2020

(NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases , a business unit of Chiesi Farmaceutici S.p.A.,

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52

The Connected Lab

APRIL 8, 2020

For patients suffering from an illness with no approved treatment, the wait can be unnerving. To this day, more than 400 million people suffer from rare diseases and 95% of rare diseases lack an FDA approved treatment 3. How is AI being applied in Drug Discovery efforts?

Pharma Companies 52

Pharma Companies Laboratories Drugs FDA Approval 52

DrugBank

DECEMBER 18, 2024

These interventions target a broad spectrum of medical conditions, encompassing chronic diseases and even substance abuse. DTx interventions include sensor-equipped wearable devices, remote patient monitoring tools, and virtual reality platforms integrated with conventional pharmaceutical treatments.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Treatment Therapies 52

The Pharma Data

MARCH 26, 2021

If approved, ponesimod will be the first therapy by Janssen for patients living with RMS with active disease defined by clinical or imaging features. MS is a chronic autoimmune inflammatory disease of the central nervous system, characterised by demyelination and axonal loss leading to neurological impairment and severe disability. [9]

Treatment 52

Treatment Pharmaceutical Companies Pharmaceuticals FDA Approval 52

The Pharma Data

DECEMBER 28, 2020

Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Annamycin for treatment of soft tissue sarcomas. .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

DECEMBER 8, 2020

Some of the funds will be used for the development of therapeutics for oncology and other serious diseases through its proprietary ImmunoTAC technology platform. The ImmunoTAC platform pairs proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites.

RNA 52

RNA Therapies Disease Protein Expression 52

The Pharma Data

OCTOBER 29, 2020

“We are honored that out of a universe of hundreds of biotechnology and pharmaceutical companies, Regeneron has been ranked #1 by Science for seven of the last 10 years,” said Leonard S. Schleifer , M.D., President and Chief Executive Officer.

Science 40

Science FDA Approval Pharmaceuticals Disease 40

The Pharma Data

AUGUST 19, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANT TM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations.

Treatment 52

Treatment FDA Approval Pharmacokinetics FDA 52

DrugBank

FEBRUARY 12, 2025

CMap utilizes gene expression profiles to connect drugs, genes, and diseases, enabling researchers to identify potential repurposing candidates based on their transcriptional signatures. They discovered that cimetidine inhibits gene expression in tumor growth and metastasis, suggesting that it could effectively slow disease progression. 

Cell Based Assays 52

Cell Based Assays Drugs Pharmacokinetics Disease 52

The Pharma Data

JUNE 28, 2021

If approved, Xarelto will be the only oral Factor Xa Inhibitor indicated in the U.S. There are currently no FDA-approved anticoagulation therapies for pediatric patients with congenital heart disease who have undergone the Fontan procedure. by Janssen Pharmaceuticals, Inc. for use in pediatric patients.

FDA 52

FDA Clinical Trials Treatment Therapies 52

The Pharma Data

JANUARY 13, 2021

Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $2.50 SOLANA BEACH, Calif., About Evoke Pharma, Inc.

Pharmaceutical Companies 40

Pharmaceutical Companies FDA Approval Clinical Trials Pharmaceuticals 40

Drug Target Review

AUGUST 3, 2023

Clinical trials are now underway for various genetic subtypes of both rare and common diseases, on the understanding that medications utilising genetic biomarkers have a significantly higher chance of success. There are clinical trials underway for genetic subtypes of rare and common diseases.

DNA 52

DNA Clinical Trials Trials Disease 52

The Pharma Data

OCTOBER 21, 2020

These findings were presented today at the 2020 Infectious Diseases Society of America (IDSA) IDWeek. D “Risk Factors” in the company’s Annual Report on Form 20-F for 2019 and as set out in GSK’s “Principal risks and uncertainties” section of the Q2 Results and any impacts of the COVID-19 pandemic. Source: GSK .

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52

Advarra

JULY 19, 2022

The sponsor is the pharmaceutical company conducting the trial. A: Working in a pharmaceutical company is the best way to learn this. Each company will have its own processes, but they will all have the same result. The sponsor-initiated IND is conducted by a pharma company seeking commercial approval.

Packaging 52

Packaging FDA Trials Regulations 52

The Pharma Data

NOVEMBER 30, 2020

We are now committed to pursuing other CGRP-mediated diseases through advancing novel investigational agents such as HTL0022562 into human studies.” We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

Practical Cheminformatics

AUGUST 3, 2023

The ability of a compound to enter the CNS can also be facilitated or hindered by certain disease states. Clintox – This dataset consists of 1483 SMILES strings and two binary labels indicating whether a molecule is an FDA-approved drug and whether a toxicity outcome has been reported.

Drugs 84

Drugs Biochemical Assays Metabolic Stability Screening Hits 84

The Pharma Data

JANUARY 21, 2021

21, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Hepatotoxicity: Hepatotoxicity has been reported in patients receiving cabotegravir or rilpivirine with or without known pre-existing hepatic disease or identifiable risk factors. cp-51575v4.

FDA Approval 52

FDA Approval Treatment RNA FDA 52

The Pharma Data

JANUARY 17, 2021

18 , 2021 /PRNewswire/ — Hanmi Pharmaceutical Co., plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields.

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

The Pharma Data

OCTOBER 14, 2020

14, 2020 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the U.S. PLYMOUTH MEETING, Pa.

FDA Approval 40

FDA Approval FDA Treatment Clinical Trials 40

The Pharma Data

FEBRUARY 25, 2022

Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction FDA approval marks a significant breakthrough for the approximately 3 million adults in the U.S. and Europe.

FDA Approval 52

FDA Approval FDA Hospitals Clinical Trials 52

The Pharma Data

SEPTEMBER 1, 2021

Approval is backed by nearly two decades of proven efficacy and safety of Janssen’s long-acting injectable portfolio of schizophrenia medicines. The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. have Parkinson’s disease or a type of dementia called Lewy Body Dementia. The Janssen U.S.

FDA Approval 52

FDA Approval FDA Treatment Clinical Trials 52

The Pharma Data

APRIL 27, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that that the U.S. About Takeda Pharmaceutical Company Limited. Mobocertinib is the first oral therapy specifically designed to selectively target EGFR Exon20 insertion mutations. Takeda’s Commitment to Oncology. 81 (0) 3-3278-3414.

FDA 52

FDA Treatment Pharmaceutical Companies Therapies 52

The Pharma Data

OCTOBER 9, 2021

Application utilizes extrapolation-based strategy across existing breadth of STELARA data in patients living with this chronic inflammatory disease. The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S.

Treatment 52

Treatment FDA Approval FDA Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 9, 2021

Johnson & Johnson and its Janssen Pharmaceutical Companies moment blazoned they will appeal the$ 572 million civil judgment entered in Cleveland County District Court in the State of Oklahoma’s action against opioid manufacturers. The Company is confident it has strong grounds to appeal this decision.

Pharmaceutical Companies 52

Pharmaceutical Companies FDA Approval Pharmaceuticals Trials 52

The Pharma Data

DECEMBER 16, 2020

Voclosporin is a novel, investigational, orally administered treatment developed to treat patients with LN, a chronic, progressive inflammation of the kidneys that is one of the most serious complications of the autoimmune disease systemic lupus erythematosus (SLE). The Company’s head office is in Victoria, British Columbia and its U.S.

Licensing 52

Licensing Licensing Pharmaceuticals Disease 52

Dark Matter Blog

AUGUST 27, 2020

In addition to the early work of Matt Disney at the Scripps Research Institute and others in the academic community showing that this was even possible, a number of pharmaceutical companies have made important advances towards drugging RNA structures to discover new therapeutics.

Small Molecule 52

Small Molecule RNA Clinical Trials Drugs 52

The Pharma Data

OCTOBER 20, 2020

Oteseconazole received FDA Qualified Infectious Disease Product Status and Fast-Track designation with NDA submission planned for 1H 2021. RVVC impacts quality of life, to a degree comparable to asthma and worse than diseases such as migraine. Top-line data remains on track for late 2020.

Treatment 52

Treatment Pharmaceuticals Clinical Trials FDA Approval 52

The Pharma Data

DECEMBER 8, 2020

This exclusivity would also benefit Treprostinil Technosphere ® , United Therapeutics’ next-generation dry powder inhalation form of treprostinil, upon FDA approval of that product for the IPF indication. Currently, there is no cure for IPF and only two drugs are approved in the United States to treat the condition.

FDA 40

FDA Treatment Drugs FDA Approval 40

The Pharma Data

JANUARY 24, 2021

Management of the Company believe that the proposed acquisition will strengthen PharmaDrug’s product pipeline, intellectual property portfolio and pharmaceutical development expertise. Food and Drug Administration (“FDA”) approval. Toronto, Ontario–(Newsfile Corp.

FDA 52

FDA Drugs Clinical Development Disease 52

The Pharma Data

MARCH 2, 2021

Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. There is no FDA-approved vaccine to prevent COVID-19.

Vaccine 52

Vaccine Clinical Trials FDA Trials 52

The Pharma Data

JUNE 26, 2021

Application seeks two pediatric indications, including an age-appropriate new weight-based oral suspension formulation to help minimize dosing errors If approved, XARELTO ® will be the first and only oral Factor Xa inhibitor indicated in the U.S. Food and Drug Administration (FDA) for the use of XARELTO ® (rivaroxaban) in pediatric patients.

Doctors 52

Doctors Treatment Hospitals Clinical Trials 52

The Pharma Data

JANUARY 29, 2021

January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints.

Vaccine 40

Vaccine Trials Pharmaceutical Companies Clinical Trials 40

The Pharma Data

MARCH 16, 2021

1,2 TREMFYA is the first and only IL-23 inhibitor therapy approved in the U.S. PsA can be a chronically painful and debilitating disease, and many PsA patients are still searching for enduring relief of their symptoms,” said Philip J. Vice President, Rheumatology Disease Area Leader, Janssen Research & Development, LLC.

Treatment 52

Treatment Disease Pharmacokinetics Therapies 52

The Pharma Data

APRIL 4, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA ® (apalutamide) in the United States. Food and Administration (FDA) approval for nmCRPC in February 2018, and received U.S. FDA approval for mCSPC in September 2019.To

Specialty Pharmacies 40

Specialty Pharmacies FDA Approval Pharmaceutical Companies Pharmacy 40

Agency IQ

OCTOBER 27, 2023

Date What’s Happening Explanation Source October 31 FDA deadline on Florida drug importation plan The FDA has said in court filings that it plans to make a ruling on Florida’s prescription drug importation plan by October 31. Within 180 days, FDA will release a report on the proceedings of the public meeting and any recommendations.

FDA 40

FDA Science Regulations Production 40